Skip Navigation

Partner with Us

From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.


Work with Us

Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.


moksha8 and CHEPLAPHARM expand their collaboration to commercialize Lexotan® in Brazil and Mexico

May 28, 2019

Through this partnership, the companies strengthen their expansion strategy in Latin American markets.

moksha8 Inc. is pleased to announce the extension of their agreement with the German based company CHEPLAPHARM Arzneimittel GmbH, in which moksha8 is appointed with exclusive rights to commercialize Lexotan® in Brazil and Mexico.

Lexotan® (Bromazepam) is a proven treatment in anxiety, tension and other somatic or psychiatric conditions associated with anxiety syndrome. This therapy belongs to the class of medications known as benzodiazepines that are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.

Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about several things even when there is no apparent reason for concern. It is a chronic illness causing patients to suffer for many years and leading to significant distress in daily life functioning. Treatment of GAD will consist of a combination of psychotherapy, behavioral therapy, and medication.

The number of persons with common mental disorders globally is increasing. According to the WHO, the total estimated number of people living with anxiety disorders in the world is 264 million, that represents nearly 3.6% of the global population. In the Region of the Americas, as many as 7.7% of the female population are estimated to suffer from anxiety disorder (males, 3.6%)1.

For moksha8, this deal not only reinforces the strategic alliance with CHEPLAPHARM, it is also a great opportunity to strengthen its CNS portfolio and experience with proven psychiatric therapies.

Under the terms of the agreement, moksha8 will begin the distribution in Brazil this year and expects a successful launch in Mexico in the 2nd Quarter of 2020.